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Summary.-Analysis of pathological data in the 10th year of follow-up of a multi-
centre trial of the management of operable breast cancer has confirmed the correla-
tion of prognosis with tumour grade, tumour size and lymph-node status. For each
factor examined there was no difference in survival between the 2 treatment groups
("watch policy" and radiotherapy) but patients in the WP group whose tumours
were of Grade II or III or >2 cm, or with lymph-node metastases, had a greater
chance of local recurrence. Cellular reaction had no relationship with prognosis,
except in patients with Grade III tumours. The clinical relevance and application
of these results are discussed.
THE Cancer Research Campaign Trial
for early breast cancer was commenced in
June, 1970. Details of the organization of
the clinical aspects of the trial have been
reported previously (Baum et al., 1972;
Cancer Research Campaign Working
Party, 1976). In summary, patients pre-
senting with clinical Stage I or Stage II
carcinoma of the breast were randomized
into a "watch policy" (WP) or radio-
therapy (DXT) group. The WP patients
had simple mastectomy alone (with careful
observation ofthe axilla) andradiotherapy
delayed until there was obvious progres-
sion or local recurrence of the disease.
Patients in the DXT group underwent
simple mastectomy with immediate radio-
therapy. Over 1000 patients were admit-
ted to each treatment group during the
5 years of accrual to the trial, and follow-
up results in the 10th year have recently
been reported (Cancer Research Campaign
Working Party, 1980a). Logrank analysis
has failed to demonstrate a significant
difference in survival between the groups,
but there was a highlysignificantincreased
risk of local recurrence in the WP group.
Although the trial was designed primarily
to test the effectiveness of the two
treatments, it was decided at the outset
to include an examination of selected
pathological factors for internal audit,
and to make an assessment of their
prognostic significance. This paper pre-
sents the results of the pathological study
and discusses the place of pathological
assessment in the future management of
breast cancer.
MATERIALS AND METHODS
Women under 70 years of age with clinical
Stage I or II (Manchester) breast cancer were
eligible for the trial, and between June 1970
and April 1975, 2800 patients were entered.
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In this multicentre trial, in which patho-
logical material was collected at over 80
hospitals in the United Kingdom, Europe,
Canada and New Zealand, it was not possible
for every specimen to be processed centrally.
All mastectomy specimens were therefore
processed initially at the hospital of origin,
and macroscopic details such as tumour size
and the number of axillary lymph nodes,
were entered on to the pathology section of
the trial pro forma (Fig. 1). Local pathologists
were asked to prepare up to 4 paraffin blocks
from each tumour, according to size, and to
block separately each lymph node found in
the axillary tail. These blocks, or multiple
representative unstained sections, were then
sent to the Central Trial Pathologists for
detailed microscopic assessment, together
with the pathology pro forma and a copy of
the localpathologist'sreport. Paraffin sections
of between 5 and 10 ,tm were stained with
haematoxylin and eosin. Because of the
many patients admitted to the trial, the
microscopic assessments were carried out in
two centres, Cambridge (GAG and GR) and
King's College Hospital, London (CWE and
TZ). All pathological assessments were made
without knowledge of clinical data.
MACROSCOPIC ASSESSMENT
This was carried out by the local patholo-
gists. Tumour size was recorded as the
greatest diameter, to the nearest cm. The
definition of the edge of the tumour was
estimated as "well, moderately or poorly
defined", and attachment to skin or deep
fascia was recorded.
The trial protocol stated that a standard
simple mastectomy should be performed
with the intent of removing all breast tissue
but avoiding interference with lymph nodes
as far as possible, so that deliberate excision
of nodes from the axilla (including any
enlarged nodes) was discouraged. In some
cases, however, the pathologist incidentally
found nodes in the tail of the mastectomy
specimen. In these cases the number was
recorded on the pathology pro forma, and
blocks or unstained slides were sent to the
Trial Pathologists.
MICROSCOPIC ASSESSMENT
Tumour grade
An assessment of tumour grade was made
only in cases ofinvasive carcinoma; intraduct
carcinomas were placed in a separate group.
Before a definite diagnosis of intraduct
carcinoma was made, all available material
was studied in detail to exclude foci of early
invasion.
The method of grading invasive carcinoma
was based on Bloom & Richardson (1957)
which was derived from a modification by
Patey & Scarff (1928) of Greenough's (1925)
original method. The tumour grade was
obtained by analysis of the following 3
histological features, a score of 1-3 being
given within each category.
Tubule formation.-Where the major pro-
portion of the tumour contained well formed
tubules with clearly visible lumens, 1 point
was given. When a moderate amount of the
tumour contained tubules, 2 points were
given. Where little or no tubule formation
was seen, the cells growing in sheets or cords,
the score was 3 points.
Nuclearpleomorphism.-An assessment was
made of the variability in size and shape of
the tumour nuclei. Tumours in which the
nuclei were regular and showed little variation
were given 1 point. A moderate degree of
variability was scored as 2 points, and
marked variation in size and shape was given
3 points.
Mitotic rate.-It was in this category that
our method differed slightly from that of
Bloom & Richardson (1957) who included
hyperchromatic nuclei as well as mitoses as
an indication of malignancy. We found it
impossible to distinguish hyperchromatic
nuclei from those which were pycnotic, and
therefore assessed only the mitotic activity.
This was graded as follows: less than 1
mitosis per high-power field (magnification
300) scored 1 point. One or 2 mitoses per
HP field scored 2 points, and cases with more
than 2 mitoses per HP field were given
3 points.
To obtain the overall tumour grade the
scores for each category were added together
and the grade allocated on the following
basis:
(a) 3-5 points: Grade I-welldifferentiated.
(b) 6-7 points: Grade II-moderately dif-
ferentiated.
(c) 8-9 points: Grade IlI-poorly differ-
entiated.
Cellular reaction
Where an inflammatory cell reaction was
present, the infiltrate contained several cell
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PATHOLOGY SHEET I I2 1 1 1_ -1 I
Patient's Name...............................................................
Hospital Number .............................................................
Please label this Sheet with the above Particulars and send it with all the Operation Specimens to
your Hospital Pathologist. Would he please complete the Macroscopic Appearances Column (below)
and prepare Blocks or Slides of the Specimens as directed in the Protocol (Pathology Section).
Macroscopic Appearance Microscopic Appowans 1
When the Macroscopic Appearance Column is filled in, would the Hospital Pathologist please
send: -
The Blocks or Slides of the Operation Specimens,
A Copy of the Hospital Pathologist's report of the macroscopic and
microscopic appearances of the breast, and
this Pathology Sheet,
TO: Breast Trial Centre or Breast Trial Centre
Pathology Department
Addenbrooke's Hospital
Cambridge.
King's College Hospital
London S.E.5.
FIG. 1. Pathology pro forma.
types. Small and large lymphocytes pre-
dominated, together with plasma cells and
immunoblasts. Histiocytes were also present,
with fewer eosinophil polymorphonuclear
Ieucocytes. Neutrophil polymorphonuclear
leucocytes were rarely found in association
with histologically preserved tumours.
The intensity of the infiltrates varied from
Breast Tumour Breast Tumour Host Response
Maximum Dimension Paget's Disease Cell Reaction 63
I53F|I1|cm Yes Severe I
No 2 Moderate 2
Not Known Mild 3
Nil4
Tumour Edge 4 Grade 5 NotKnown
Well defined I 1
Moderately defined 2 -
PoorIV defined 24 2
Not known 4 3 3
Attachment to Skin Attachment to Skin 6
Yes Yes H
No 2 No 2
Not Known Not Known
Attachment to _ Attachment to _ Deep Fascia s6 Deep Fascia 61
Yes Yes
No 2 No 2
Not Known 3 Not Known
Number of Axillary Nodes Numbw of Axillary Nodes
Found Involved
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case to case. In view of the large number of
cases, and the non-standardized collection
and preparation of histological sections, it
was not possible to use a quantitative
method. The assessment was, therefore,
carried out on a semi-quantitative basis,
using 4 degrees of intensity:
Marked.-This was characterized by a
wide diffuse band of inflammatory cells
investing the whole of the periphery of the
tumour, many cells in thickness. The tumour
stroma also contained a heavy cellular
infiltrate, so that the overall impression in
these cases was that the inflammatory
component was greater than the tumour
component. Foci of lymphoid cells were also
frequently seen in the adjacent connective
tissue.
Moderate.-The reactions were graded as
moderate when the whole tumour was
surrounded by inflammatory cells which
formed a diffuse band several cells wide, but
not as extensive as that seen in a marked
reaction. The stroma also contained a
moderate infiltrate, but the mass of reactive
cells never exceeded that of the tumour.
Slight.-The cellular infiltrate in a slight
reaction consisted of a thin but definite
diffuse band of inflammatory cells surround-
ing the whole tumour, with only occasional
cells in the stroma. Cases with more intense
focal infiltrates were also included in this
category if the diffuse reaction at the peri-
phery of the tumour could only be graded as
slight.
Nil.-In nearly all tumours a few inflam-
matory cells can be found at the periphery.
Included in this category, therefore, were all
cases in which scanty foci of cells were
found, but in which large parts of the
periphery of the tumour were unassociated
with any reaction.
Lymph-node status
The representative blocks or sections sent
to the Trial Pathologists were examined
carefully and the presence of lymph-node
metastases recorded.
VERIFICATION
All these assessments, because of their
subjective nature, were double-checked. This
was achieved in two ways:
Cross-checking
Because ofthe large number ofcases it was
not always possible to carry out cross-checks,
but in a substantial proportion, where the
initial scoring was carried out by the original
Trial Pathologists (CWE, GAG, GR) a
second assessment was performed by a
different pathologist (TZ) without knowing
the initial results.
Double-checking
In those cases not cross-checked by TZ, a
second assessment was carried out by the
original pathologist, on a separate occasion,
without knowing the initial results.
There was overall agreement in -85% of
cases. Where there was disagreement, the
sections were checked a third time, after
which agreement was reached by concensus
after discussion.
CLINICAL DETAILS
These have been reported in full previously
(CRC Working Party, 1976 1980a). Of the
2800 patients admitted to the Trial, 537 were
excluded because of ineligibility for various
reasons (CRC Working Party, 1980a) leaving
2243 "evaluable" cases.
RESULTS
To date, full pathological data are
available in 1897 patients, 1562 of whom
are in the evaluable group. The collection
and assessment ofpathological data on all
patients is not yet complete for logistical
TABLE I.-Comparison of treatment groups
Total
Pathological material assessed
Pathological size < 2 cm
Histological Grade III
Histologically involved nodes
Cellular reaction-"nil"
Evaluable patients 2243
r-
WP (%) DXT (%)
1140 (100) 1103 (100)
800 (70) 762 (69)
204 (18) 204 (18)
239 (21) 216 (20)
111 (10) 117 (11)
536 (47) 541 (49)
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reasons which are discussed in a separate
communication (CRC Working Party,
1980b). Table I shows that no bias by
treatment group has occurred in the
selection of pathological material, and
confirms the reliability of the randomiza-
tion. The statistical results below are
based on the 1562 evaluable. Survival
and local-recurrence-free curves were con-
structed by the life-table method and
compared using the logrank test (Peto
et al., 1977). Survival analyses include
deaths from all causes, but local recurrence
was only counted if it occurred before or
at the same time as distant recurrence.
Metastases at any of the following sites
were counted as local recurrences: chest
wall, ipsilateral axilla, ipsilateral supra-
clavicular area and internal mammary
nodes. Confirmation of axillary recurrence
was defined as "persistence" of a lymph
node or the appearance and progressive
enlargement-, or fixation of a node. A
Survival
(X) 1iC
80
60
40
20
detailed description of the trial data
analysis has already been published (CRC
Working Party, 1980a).
The relationship between tumour size
and survival is shown in Fig. 2. Prognosis
worsens with increasing tumour size
(P<O0001) but as shown in Fig. 3, there
is a significant relationship between tu-
mour size and grade. When treatment
policies were compared within each of the
3-pathological size categories (<2, 2-4,
> 4 cm) no significant difference in sur-
vival was found.
The smaller the tumour, the less
chance of local recurrence, but the added
risk of local recurrence in the WP group
increased with tumour size (Table II).
The definition ofthe edge ofthe tumour
had no influence on the survival of
patients, nor did the attachment of the
tumour to a deep fascia. However, those
patients whose tumours were macro-
scopically attached to the skin had a
Pathologicol Size
- <2cm
2-4cm
>4cm
No. at risk
408 39
818 78d
251 23.
9
6
3
378
736
208
357
665
187
341
593
171
304
496
148
206
347
89
107
201
50
44 <2cm
74 2-4cm
18 >4cm
0 1 2 3 4 5 6 7 8
Years
FI"G. 2. Survival rates accor(diing to ttumour (liameter ( x2 for trend = 27 -0, P<0 001). In this and
subsequent figutres tfhe "no. at risk" represents the ntumber of patients alive (or recurrence-free
in Figs 7 an(l 8) at entry ainl anntually tlhereafter. This number (lecreases over the years, as there
are fewN-er patients with relevant trial times.
I
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FIG. 3. Relationship between tumour
and grade of malignancy. (The figur
brackets represent the percentag
patients in each category. x2=
P<0- 001).
significantly worse survival (Fig. '
parison of the two treatment
stratified by attachment to t]
showed no statistically significan
ence.
The relationship between tumoi
and survival is shown in Fig. 5. TI
highly significant correlation,
progressive worsening of prognoe
Intraduct and Grade I invasive car
to Grade III invasive carcino
< 0-001). When divided accor(
grade, there was no significant d
in survival between the 2 treatment
>4 groups. Fig. 6 shows the results in
Grade I and III.
The overall influence of grade on local
recurrence was similar to that on survival;
the risk increasing with the grade of
malignancy. However, when the treatment
2-4 policies were compared within each grade,
it was apparent that there were fewer
local recurrences in the DXT group, but
only in patients with Grades II and III
tumours (compare Figs 7 & 8). Table III
compares the hazard ratio (HR) of local
recurrence for patients in the WP group
and the DXT group when divided accord-
ing to grade and size of tumour.
<2 Preliminary analysis of the cell-reaction
data suggested a division into two groups;
the "nil" and "slight" infiltrates forming
a "mild" reaction group and the "moder-
ate" and "marked" infiltrates forming a
r size "severe" group. No significant difference
res in in survival between these two categories
re of
'24*5, was found (Fig. 9). However, since the
severe cell reactions tend to be associated
with the less differentiated tumours (Fig.
4). Com- 10) there was a possibility that the effect
groups of cell reaction was masked by the
he skin, influence of tumour grade. Accordingly, a
Lt differ- separate analysis was carried out to test
the effect of cell reaction within each
ur grade tumour grade. The only significant asso-
here is a ciation was found in Grade III tumours
with a (Fig. 11 and Table IV); patients in the
sis from severe group having a better survival
cinomas than those in the mild group (P= 0 002).
tmas (P In fact, the survival curve for Grade III
ding to severe cell-reaction tumours is closely
ifference similar to that for all Grade II tumours
TABLE II.-Comparison of watch policy and radiotherapy on local-recurrence-free rates in
patients grouped according to the pathological size of tumour
Logrank analysis
Tumour 5-year rate (%) ± s.e. WP
diameter , A
(cm) WP DXT 0 E
<2 76-5+3-0 90-2+2-2 53 36-9
2-4 68-5+2-4 87-6+1-8 135 92-7
>4 56-3+4-5 89-2+3-1 59 36-1
* Hazard ratio = (O/E) WP/(O/E) DXT.
DXT
0 E
24 40-1
48 90-3
13 35-9
HR* x2 _P
2-4 13-7 <0-001
2-75 40-2 <0-001
4-5 81-7 <0-001
I II
(15) (17) (1 8)
(45) (55) (61)
(40 (28)
660CRC BREAST TRIAL: CLINICO-PATHOLOGICAL ASPECTS
Survival
(%
661
100
60 * Not attached
~~-. Attoched to skin
40
20
No. at risk
1186 1140 1069 978 899 774 530 301 115 Not attached
145 140 131 116 100 81 57 33 12 Attached to skin
0 1 2 3 4 5 6 7 8
Years
FiG. 4. Survival r'ates of patients according to tumouir attaclhment to skin ( x2 5- 64, P < 0-02).
36 36 35
176 174 167
865 819 755
423 372 329
0 1
*_= Grode I
**-*- ...~_Grade I I
Grade III
34 32 28 18 6 I/D
161 139 93 51 15 Grade I
684 576 373 198 82 Grade II
298 258 185 114 38 Grade II
5 8
Years
FIG. 5.--Survival rate for intra(luct carcinoma (I/1)) and for invasive carcinoma, Grades I, II an( III.
( X2 for trend= 57 7, P < 0 *001).
(Fig. 12). However, neither the Grade III (Fig. 13). When the two treatment
severe cell-reaction subgroup nor the policies were compared within each of the
Grades II and III combined severe cell- cell-reaction categories, there was no
reaction subgroup have a better survival significant difference in survival.
than all the other patients combined The risk of local recurrence was not
Survival
(S) 100
80
60
40
20
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Survival - WP
1 I00 - DXT
( 8;) 1 [ < ; ~ ~ ~ ~ ~~'*~- ~ + * Grade I
60
Grade III
40
No, at Risk Grade 1
93 92 92 89 87 75 47 23 5 WP
20 86 85 83 79 75 66 47 29 11 DXT
Grade III
239 224 201 172 153 137 100 60 21 WP
216 200 172 158 146 121 85 55 19 DXT
0 1 2 3 4 5 6 7 8
Years
FIG. 6.- Patients with Grade I or Grade III tumours: survival rates in WP and DXT groups (Grade
I; x2=jl74,P=O019:Grade1II; X2=0-O,p=0-99).
Local
Recurrence-Free
(%) 100 3~... - ~ - - DXT
80
60
40
20
No. at Risk
93 92 87 84 82 80 66 40 15 WP
86 85 80 75 70 66 58 41 21 DXT
0 1 2 3 4 5 6 7 8
Years
FIe. 7. Patients with Grade I tumours: local-recurrence-free rates in WP and DXT groups ( X2 =0*04,
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Local
Recurrence-F ree
(X . ZA
N~'' A ' - ~ 'S' ~ *~ ~ ~~ ~ ~*~ ~ ~ ~ ~*~~ ~ ~ ~* ~ ~ ~ ~^ - DXT
,__ WP
No. at Risk
451 424
440 41 9
- Grade IT
371
402
332 293 259 203 132 74 WP
360 332 294 235 134 74 mXT
Grade III
239 211 173 141 125 111 96 64 35 WP
216 199 174 156 142 127 97 69 39 DXT
0 1 2 3 4 5 6 7 8
Years
FIG. 8. Patients with Grade II (A) or III (A) tumours: local-recurrence-free rates in WP and DXT
groups (Gradell; X2=59-3,P<0-001:Grade III; X2=35-7,P<0-001).
TABLE III.-Hazc
for local recur
limits in bracket
Tumour diam. ,-
(cm)
n
<2 1
(0-:3
n
2-4 1
(0-4
11
>4 0
(0- 1
* P<0-05
**P<0.01
influenced by th
reaction around
increased risk of
WP patients was,E
and severe groups.
zrd ratios for WP/DXT Fig. 14 shows survival curves for patients
rence (9500 confidence with histologically negative lymph nodes
s) and those with involved nodes. Survival
Pathiological grade is significantly better in patients with
negative nodes (P <0-001), but there
I II III was no difference in survival between the
71 240 93 two treatment groups when stratified
9-5) (1.3 4.3) (1-295.) according to the pathological involvement
79 463 270 of the node sample.
-24 2 7-4** 3.-5* Patients whose nodes contained metas-
-4-0) (1-7-4.4) (2-0-6-1)
26 143 81 tatic carcinoma had a greater risk of local
-91 9-89** 3 35** recurrence than those whose nodes were
l-7-0) (3.5-28) (1-4-8-2) negative (P<0-002). When the treatment
policies were compared in the two node
groups, the increased risk of local recur-
e severity of the cell rence for patients who had not received
the tumour, and the radiotherapy was greater for those with
local recurrence in the involved nodes (hazard ratios 1-9 and 3-6
similar in both the mild for those with negative and positive nodes
respectively) (Table V).
In 418 of the 1562 cases, axillary
lymph nodes were identified by the local
pathologist. The numbers are too small to
carry out an analysis according to the
overall number of nodes involved, but
DISCUSSION
Tumour size has been shown previously
to influence prognosis (Cutler et al., 1969;
-1 luu
80
60
40
20
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...... ........ . Severe
_ Mild
1 248
1 1 1
1146
99
1 045
92
879 579 312 1 1 1 Mild
88 68 45 21 Severe
0 1 2 3 4 5 6 7 8
Years
FIG(:. 9. Suurvival rates according to thte severity of cell reactioni ( x2 =-O 77, P=0 *38).
U-,
0
0o
0
0
I10
I)
C)
FIG. 10. Relationslip between tumour grade
and cell reaction to the tumour.
Fisher et al., 1969; Blamey et al., 1979)
patients with small tumours having better
survival than those with large tumours.
In this study, tumour size was measured
in formalin-fixed material by the local
pathologists. Despite the many observers,
this study confirms the previous reports,
showing a progressive worsening of sur-
vival with increasing tumour size (Fig. 2).
However, tumour size may not be an
independent factor, since there is a
significant correlation between size and
grade, Grade I tumours tending to be
smaller than Grade III (Fig. 3).
In addition to measuring tumour size
and sampling lymph nodes, the local
pathologists were asked to assess the
definition of the tumour edge, and note its
attachment to deep fascia or skin. Curious-
ly, the only one ofthese factors to influence
prognosis is attachment to skin (Fig. 4).
There would seem to be little value in
recording tumour definition in future
studies, but attachment to deep fascia
may be of practical importance to the
surgeon.
Although assessment of histological
tumour grade was advocated over 50
years ago as a useful prognostic factor in
human breast cancer (Greenough, 1925;
Patey & Scarff, 1928) it has never achieved
universal acceptance. This is despite
convincing evidence from Bloom that
there is a clear correlation between a low
grade of malignancy and better survival
(Bloom, 1950a, b, 1962; Bloom & Richard-
Survival
(X)
100
80
60
40
20
No. at risk
1 392 1 335
126 122
664CRC BREAST TRIAL: CLINICO-PATHOLOGICAL ASPECTS
332 290 253 229 190 130 81
87 79 72 66 64 52 31
1 2 3 4 5 6 7
Years
FIG. 11. Patients with Gra(de III ttumours; survival rates aecor(ling to the sever-ity of cell reaction
( X2=9-23, P=0-002).
TABLE IV.-Influence of cell reaction on
s8urvival in tumour grades I, II and
III
Overall
Gra(le 1l 87 )0+2-5
Gradle II 71-6 + 1*5
Grade III 60 2 + 2 - :3
* Of the 178 patients
classe(l as severe.
ar rate (%) + se
Cell reaction
Mild Severe
* *
71-7+1-6 69-7+8-0
57-1+2-6 71 4+4 7
in Grade I orly 2 were
son, 1.957) the influence ofgrade persisting
over 10- and 20-year follow-ups (Bloom &
Field, 1971). This association has been
confirmed by several other studies (Wolff,
1966; Hamlin, 1.968; Champion et al.,
1972; Elston et al., 1980) and Eichner
et al. (1970) have shown good compara-
bility between the Bloom method and the
nuclear-grading method of Black et al.
(1955). The results from this study
provide further confirmation, based on a
large number of patients, that the histo-
logical grade of a tumour has a highly
significant influence on the prognosis of
the patient (Fig. 5). It is difficult to make
direct comparisons with Bloom & Richard-
son's study (1957) particularly as the
overall survival at 5 years in our series is
considerably higher (71% vs. 50%o). How-
ever, in both series the 5-year survival of
patients with Grade I tumours (CRC, 87%,
Bloom & Richardson, 75%o) is considerably
better than those with Grade III tumours
(CRC, 60%, Bloom & Richardson 32%).
Although they account for only 12% of
the invasive carcinomas, the fact that the
survival curve for Grade I tumours is the
same as for intraduct carcinomas, con-
firms the very good prognosis for patients
with these tumours. It will be of interest
to note whether this good prognosis is
maintained when a full 10-year follow-up
of all patients is obtained.
The term "medullary carcinoma" has
been used to denote a particular type of
breast cancer characterized by a circum-
scribed margin, relatively poor histological
Survival
(x)
100
80
60
40
20
* %tf 0* * Severe
*@@"-- -Z@-@......@ @-*-@ .. . evr
isk No. at Ri
359
0
9 Mild
24 Mild
13 Severe
8
665C. W. ELSTON ET AL.
*vival
,,,
80*
60 .* Grode I; II &
40
20
No. at Risk
Grade I II &
91 87 79 72 66 64 52 31 13 severe CR
891 865 819 755 684 576 373 198 82 All Grode II
0 1 2 3 4 5 6 7 8
Yeors
FIG. 12.-Comparison of survival rates of patients with a severe cell reaction in a Grade III tumour
and all patients with Grade II tumours ( X2=0 37, P=0054).
Survival
()100
80
60
AO
No. ot risk
91 87
124 120
I' * t -: . . ... : s;_ Grade III Severe CR
..... ''-"* Grade II & III Severe CR
*._.o All other
79 72 66 64 52 31 13 Grode III Severe CR
110 98 91 87 67 44 20 Grade II & III Severe CR
1249 1147 1046 880 580 315 112 All other
7
Years
FIG. 13.-Comparison of the survival rates of patients having a severe cell reaction and Grade II
or III tumour with all other patients whose pathology has been assessed (xX2=0 89, P=0.35).
The curve for patients having a severe cell reaction and Grade III tumour (Fig. 12) is superimposed.
differentiation and an intense lympho-
plasmacytic infiltrate in the stroma.
Despite the poor differentiation, this type
of tumour has been reported to have a
relatively favourable prognosis (Moore &
Foote, 1949; Bloom et al., 1970; Ridolfi
et al., 1977) and there has been speculation
that the lymphoplasmacytic infiltrate
666
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(X)
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80
60
40
20 No. at risk
97 93
93 90
117 103
111 107
93 91
81 73
96 86
96 84
89 78 60 36
72 66 52 28
78 61 43 22
76 56 28 1 1
v _ . 0 D(T Node -ye _~. wP
**.*CTNode +v
-- WP
13 DXT
9 WP ve
6 DXT
4 WP +ve
0 1 2 4 7
Yeors
FiG. 14.-Comparison of survival according to treatment policy in patients with uninvolved nodes (-ve) ( X2 = 1 *88, P = 0* 17) and in patients with histologically involved nodes (+ve) (X2 =0*24, P=0 63).
TABLE V.-Comparison between WP and DXT local-recurrence-free rates (%) in patients
with histologically assessed nodes
Logrank analysis
5-year rate (%) s.e. WP DXT
n Overall WP DXT 0 E 0 E HR x2 P
Node negative (179) 87-0+2-5 81-2+4-2 92-3+2-8 19 13-9 11 16-1 1-88
(0 9-4 0) 3-55 0-06
Node positive (220) 73*2+3*2 58-9+3-4 88-2+3-4 43 25-4 14 30*6 3*62 20-1 <0*001
(2*0-6*7)
represents an immunological host-defence
mechanism (Berg, 1959). Ridolfi et al.
(1977) showed a significantly better sur-
vival at 10 years for medullary carcinoma
(84%) than for non-medullary carcinoma
(63%) whilst Bloom et al. (1970) demon-
strated persistence of this effect in a
20-year follow-up (medullary 48% sur-
vival, non-medullary 16%). It has also
been shown that, when the intensity of
the cell infiltrates is assessed in all the
tumours in a series, the prognosis is better
with the more severe reaction (Black et al.,
1955; Berg, 1959; Hamlin, 1968). In the
CRC trial, an assessment of cell reaction
was made in all cases of invasive car-
cinoma. For the purposes of analysis, the
4 degrees of infiltrate were combined to
form 2 reaction groups, "mild" and
"severe". The survival curves for both
groups were identical (Fig. 9) indicating
no advantage from severe reaction. In
common with previous reports (Champion
et al., 1972; Blamey et al., 1979) the severe
infiltrates were usually associated with
less differentiated tumours (Fig. 10), and
the survival analysis may have been
influenced by the inclusion in the mild-
reaction group of well differentiated
tumours with a morefavourable prognosis.
Accordingly, the effect ofcell reaction was
tested within each grade, and only in
Survival
(X)
100
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Grade III tumours did patients in the
severe-reaction group have a better sur-
vival (Fig. 11). A precise comparison with
medullary carcinoma cannot be made in
this study, as histological typing was not
undertaken. The closest approximation to
medullary carcinoma is the subgroup
composed of tumours of Grade II and III
exhibiting a severe cell reaction; patients
in this group did not have a better
survival than other patients in the study
(Fig. 13). This casts doubt on the conten-
tion that it is the lymphoplasmacytic
infiltrate which is responsible for the
relatively favourable prognosis of medul-
lary carcinoma (Berg, 1959). In this study
the only predictive value of a severe cell
reaction lies in the fact that its presence
in a Grade III tumour improves the
survival curve to that of the overall
Grade II group (Fig. 12). These results
suggest, in common with some previous
reports (Wolff, 1966; Blamey et al., 1979)
that assessment of cell reaction provides
limited prognostic information.
The relationship between regional
lymph-node metastasis and prognosis in
breast cancer is well established (Cutler
et al., 1969; Fisher et al., 1975). Although
the removal of axillary lymph nodes was
discouraged, nodes were removed inci-
dentally in 27% of cases. The survival
curves confirm the significantly poorer
prognosis of patients with histologically
involved axillary nodes (Fig. 14).
The most important point to emerge
from follow-up in the tenth year of this
trial is that, although there is no difference
in survival between patients in the 2
treatment groups, those in the DXT
group had fewer local recurrences (CRC
Working Party, 1980a). This poses a
therapeutic dilemma. Should all patients
undergoing simple mastectomy receive
immediate post-operative radiotherapy to
spare some 20-30% the anxiety of recog-
nizing early failure of treatment, or could
delayed radiotherapy eventually achieve
the same degree of local control and thus
spare most women unnecessary prophyl-
actic radiotherapy? Consideration of the
pathological data clarifies this problem.
Local recurrence rates are significantly
higher in the WP group for patients with
Grade II and III tumours, but not Grade I
tumours (Figs 7 and 8, Table III) and for
patients with histologically involved nodes
(Table V). Furthermore, within Grades II
and III the risk tends to increase with
increasing tumour size (Table III). Im-
mediate post-operative radiotherapy could
certainly be recommended for patients
with large Grade II or III tumours and
histologically involved lymphnodes, whilst
patients with small Grade I tumours and
histologically negative nodes may not
require adjuvant radiotherapy. Thus, for
the first time, data are presented that may
allow the clinician to select the extent of
local therapy on the basis of histopatho-
logical criteria.
The purpose of the pathological part of
the trial was to test certain established
and potential pathological factors for
prognostic significance. The results to date
indicate that tumour size, histological
grade and lymph-node metastasis provide
significant markers of survival in breast
cancer. This is in close agreement with the
prospective study of Blamey et al. (1979)
who have used these factors to devise an
index of poor prognosis. They can also be
used to determine local treatment policy.
In planning the next generation of trials
of adjuvant therapy, these factors should
play an important part in the stratification
of patients and therapy.
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668CRC BREAST TRIAL: CLINICO-PATHOLOGICAL ASPECTS 669
more to acknowledge the very general financial
support of the Cancer Research Campaign.
REFERENCES
BAUM, M., EDWARDS, M. H. & MARGAREY, C. J.
(1972) Organisation of clinical trial on national
scale: Management of early cancer of the breast.
Br. Med. J., iv, 476.
BERG, J. W. (1959) Inflammation and prognosis in
breast cancer. Cancer, 12, 714.
BLACK, M. M., OPLER, S. R. & SPEER, F. D. (1955)
Survival in breast cancer cases in relation to the
structure of the primary tumor and regional
lymph nodes. Surg. Gynecol. Ob8tet., 100, 543.
BLAMEY, R. W., DAVIES, R. J., ELSTON, C. W.,
JOHNSON, J., HAYBITTLE, J. L. & MAYNARD, P. V.
(1979) Prognostic factors in breast cancer: The
formation of a prognostic index. Clin. Oncol.,
5, 227.
BLOOM, H. J. G. (1950a) Prognosis in carcinoma of
the breast. Br. J. Cancer, 4, 259.
BLOOM, H. J. G. (1950b) Further studies on prog-
nosis of breast carcinoma. Br. J. Cancer, 4, 347.
BLOOM, H. J. G. (1962) The role of histological
grading in the study of breast cancer. Acta Un.
Int. Cancer, 18, 843.
BLOOM, H. J. G. & FIELD, J. R. (1971) Impact of
tumour grade and host resistance on survival of
women with breast cancer. Cancer, 28, 1580.
BLOOM, H. J. G. & RICHARDSON, W. W. (1957)
Histological grading and prognosis in breast
cancer: A study of 1409 cases of which 359 have
been followed for 15 years. Br. J. Cancer, 11, 359.
BLOOM, H. J. G., RICHARDSON, W. W. & FIELD,
J. R. (1970) Host resistance and survival in
carcinoma of breast: A study of 104 cases of
medullary carcinoma in a series of 1,411 cases of
breast cancer followed for 20 years. Br. Med. J.,
iii, 181.
CANCER RESEARCH CAMPAIGN WORKING PARTY
(1976) Management of early cancer of the breast.
Report on an international multicentre trial
supported by the Cancer Research Campaign.
Br. Med. J., i, 1035.
CANCER RESEARCH CAMPAIGN WORKING PARTY
(1980a) Cancer Research Campaign (King's/
Cambridge) trial for early breast cancer. A
detailed update at the tenth year. Lancet, i, 55.
CANCER RESEARCH CAMPAIGN WORKING PARTY
(1980b) Trials and tribulations: Thoughts on the
organisation of multicentre clinical studies. Br.
Med. J. 280 918.
CHAMPION H. R., WALLACE, I. W. J. & PRESCOTT,
R. J. (1972) Histology in breast cancer prognosis.
Br. J. Cancer, 26, 129.
CUTLER, W. J., BLACK, M. M., MORK, T., HARVEI,
S. & FREEMAN, C. (1969) Further observations on
prognostic factors in cancer of the female breast.
Cancer, 24, 653.
EICHNER, W. J., LEMON, H. M. & FRIEDELL, G.
(1970) Tumor grade in the prognosis of breast
cancer. Nebraska Med. J., 55, 405.
ELSTON, C. W., BLAMEY, R. W., JOHNSON, J.,
BISHOP, H. M., HAYBITTLE, J. L. & GRIFFITHS, K.
(1980) The relationship ofoestradiol receptor (ER)
and histological tumour differentiation with
prognosis in human primary breast carcinoma. In
Breast cancer-Experimental and Clinical Aspects.
(Eds Mouridsen & Palshof). New York: Pergamon
Press. p. 59.
FISHER, B., SLACK, N. H., BRoss, I. D. J. & co-
operating investigators (1969) Cancer ofthe breast
Size of neoplasm and prognosis. Cancer, 24, 1071.
FISHER, B., SLACK, N., KATRYCH, D. & WOLMARK,
N. (1975) Ten year follow-up results of patients
with carcinoma of the breast in a co-operative
clinical trial evaluating surgical adjuvant chemo-
therapy. Surg. Gynecol. Obstet., 140, 528.
GREENOuGH, R. B. (1925) Varying degrees of malig-
nancy in cancer of the breast. J. Cancer Res., 9,
453.
HAMLIN, I. M. E. (1968) Possible host resistance in
carcinoma of the breast: A histological study.
Br. J. Cancer, 22, 383.
MOORE, 0. S. & FOOTE, F. W. (1949) The relatively
favourable prognosis of medullary carcinoma of
the breast. Cancer, 2, 635.
PATEY, D. H. & SCARFF, R. W. (1928) The position
of histology in the prognosis of carcinoma of the
breast. Lancet, i, 801.
PETO, R., PIKE, M. C., ARMITAGE, P. & 6 others
(1977) Design and analysis of randomized clinical
trials requiring prolonged observation of each
patient-II Analysis and examples. Br. J.
Cancer, 35, 1.
RIDOLFI, R. L., ROSEN, P. P., PORT, A., KINNE, D. &
MIKE, V. (1977) Medullary carcinoma of the
breast: A clinicopathologic study with 10 year
follow-up. Cancer, 40, 1365.
WOLFF, B. (1966) Histological grading in carcinoma
of breast. Br. J. Cancer, 20, 36.
45